Virogenomics working on MS Drug Target

This article in the Oregonian talks about a biotech startup called Virogenomics that is working on a target for an MS drug. It works by preventing T-cells, the attacking force in the immune system, from going after the proteins that coat most nerve cells. Just another company to keep an eye on.